Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
To determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients attending their routine clinical visit at sites specialized in the management of severe asthma in several countries in the AstraZeneca International Region. The prevalence of an atopic phenotype and the status of asthma control, will also be studied. It is expected that this study will contribute to the understanding of severe asthma, ultimately helping to inform therapeutic decisions and addressing patients' needs.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patient, aged 12 years or older by the time of study entry
Patient visiting a participating center for a routine clinical appointment
Patient is willing and able to provide a blood sample for IgE and eosinophil levels determination as part of their routine clinical visit
Diagnosis of severe asthma for at least one year as defined by:
Treatment with guidelines-suggested medications for Global Initiative for Asthma (3) steps 4-5 asthma
Patients or their legal guardian, who voluntarily sign and date the informed consent form prior to study entry.
You may not be if
Patients with a diagnosis of chronic obstructive pulmonary disease or other chronic respiratory condition beyond severe asthma
An acute or chronic condition that, in the investigator's opinion, would limit the patient's ability to participate in this study Patients who are currently under a biologic therapy to treat their severe asthma